# Saffron Attention Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/saffron-attention-randomized-trial-evidence-review
Category: evidence-review
Summary: Saffron Attention Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are syst
Last reviewed: 2026-08-07
Reviewed by: Migaku Evidence Review
# Saffron Attention Randomized Trial: What the Evidence Says

## Quick Answer

Saffron Attention Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence | systematic review | 1 | 2026-04-27 | 10.1002/hsr2.72212 |
| From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases | narrative review | 3 | 2026-03-15 | 10.3390/ph19030484 |

## What The Sources Report

- Difficulties in accessing healthcare, their high costs, personal preferences, and the perceived safety of medicinal herbs have contributed to the increased usage of herbalism. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
- Given their popularity, it is crucial to have up-to-date risk and benefit assessments on these herbal products. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
- In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients-crocins, crocetin, safranal, and picrocrocin-as pharmacologically relevant compounds. [Campos Catarina (2026); evidence level 3]
- By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron's potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. [Campos Catarina (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For saffron attention randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Hasheminasab Fatemeh Sadat (2026). Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence. DOI: 10.1002/hsr2.72212. PMCID: PMC13121846. PMID: 42057871. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13121846/
- Campos Catarina (2026). From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases. DOI: 10.3390/ph19030484. PMCID: PMC13029429. PMID: 41901329. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029429/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.